BMRN

$56.05

Market ClosedAs of Mar 17, 8:00 PM UTC

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$56.05
Potential Downside
38.4%
Whystock Fair Value$34.54
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Paci...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$10.78B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
31.14
Beta
Defensive asset. Lower volatility than the S&P 500.
0.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
5.94%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
3.25

Recent News

Motley Fool
Mar 17, 2026

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Mar 17, 2026

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally

This clinical-stage biotech develops small-molecule therapies targeting NASH, obesity, and related metabolic diseases.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Mar 15, 2026

Hedge Fund Boone Capital Initiated a Stake in HealthEquity. Is the Stock a Buy?

HealthEquity delivers cloud-based healthcare savings solutions to employers and individuals, with a broad client network across the U.S.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 14, 2026

BioMarin Pharmaceutical (BMRN) Receives FDA Approval for Expanded Use of PALYNZIQ in Adolescents

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best get-rich-quick stocks to buy according to hedge funds. On February 27, the US FDA approved BioMarin’s supplemental Biologics License Application for PALYNZIQ, expanding its use to include adolescents aged 12 and older with phenylketonuria/PKU. This medication remains the only approved enzyme substitution therapy designed to reduce […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 13, 2026

BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference

BioMarin Pharmaceutical (NASDAQ:BMRN) executives highlighted a three-pillar strategy focused on growth, innovation, and “value commitment” during a fireside chat hosted by Leerink Partners’ Joe Schwartz, pointing to recent revenue momentum, multiple clinical milestones, and the planned addition of A

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.